For the first time since 1965, Berkshire Hathaway has made a major trade under the direction of someone other than former CEO Warren Buffett. The conglomerate recently sold roughly 1.65 million shares of DaVita Inc. (NYSE: DVA), valued at about $200 million, under newly appointed CEO Greg Abel, who took the helm of the company in 2026, reported the International Business Times. However, this does not necessarily mean that Abel is countering the wishes of his former mentor. In fact, it may simply represen ...

Core Viewpoint - Berkshire Hathaway has made significant adjustments to its investment portfolio in the fourth quarter, including new positions and changes in existing holdings [1] Group 1: New Investments - Berkshire Hathaway has initiated a position in The New York Times [1] Group 2: Increased Holdings - The company has increased its stakes in Chubb, Chevron, Domino's Pizza, and Lamar [1] Group 3: Reduced Holdings - Berkshire Hathaway has reduced its investments in Amazon, Bank of America, DaVita, Pool Corp., and Aon Plc [1] Group 4: Major Holdings - The company continues to hold significant positions in Apple, American Express, US Bank, Coca-Cola, and Chevron [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. ...

Core Viewpoint - DaVita Inc. is a leading healthcare provider in kidney care services, facing challenges from rising costs and a recent ransomware attack, but has shown strong quarterly performance leading to a year-to-date stock increase of 24% [1][2]. Company Overview - DaVita Inc. specializes in kidney care services, including dialysis treatments for chronic kidney failure patients, and is headquartered in Denver, Colorado with a market capitalization of $9.94 billion [1]. Stock Performance - Over the past year, DaVita's stock has declined by 18.2%, but it has rebounded with a 24% increase year-to-date [2]. - The stock reached a 52-week low of $101 on January 14, but has since increased by 39.4% from that level [2]. - In comparison, the S&P 500 Index gained 14% over the same period, indicating underperformance relative to the broader market [3]. Financial Results - DaVita reported a 9.9% year-over-year increase in Q4 revenue to $3.62 billion, driven by a 9% growth in dialysis patient service revenues to $3.40 billion [3]. - The company anticipates headwinds due to the expiration of the Affordable Care Act, but expects to offset these challenges with the elimination of cyber-incident impacts in 2025 [3]. Earnings Projections - Analysts expect DaVita's EPS to increase by 20.5% year-over-year to $2.41 for the current quarter, with further annual increases projected to $14.16 in fiscal 2026 and $16.90 in fiscal 2027 [4]. Analyst Ratings - Among eight Wall Street analysts covering DaVita, the consensus rating is a "Hold," with two "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [5]. - The ratings configuration has become slightly more bullish, with the number of "Strong Buy" ratings increasing from one to two [5].

Core Viewpoint - Berkshire Hathaway has two strong investment opportunities in DaVita and Kraft Heinz, while UnitedHealthcare Group is currently not recommended for investment. Group 1: DaVita (DVA) - DaVita has been a long-term investment for Berkshire Hathaway since 2011 and is showing signs of recovery after beating quarterly expectations and providing optimistic 2026 earnings guidance [5][7]. - The current stock price of DaVita is $140.71, with a market cap of $9.9 billion and a gross margin of 27% [6][7]. - DaVita's earnings per share for the year are expected to be between $13.60 and $15, suggesting it is trading at a low multiple of around 9 times forward earnings, compared to its historical range of 13 to 14 times [8]. Group 2: Kraft Heinz (KHC) - Berkshire Hathaway holds a 27% stake in Kraft Heinz, valued at approximately $7.5 billion, but has faced significant losses on this investment and may consider selling part of its stake [9][10]. - Kraft Heinz is currently trading at about 9 times forward earnings, which is a discount compared to its peers, presenting a potential opportunity for new investors [11]. - The company plans to split into two entities to unlock value, similar to Kellogg's successful separation in 2023, which could enhance shareholder value [12]. Group 3: UnitedHealthcare Group (UNH) - Berkshire Hathaway purchased 5 million shares of UnitedHealthcare Group, but the stock has faced challenges due to lower-than-expected Medicare Advantage payment increases, leading to a drop in stock price from $350 to around $280 [13][14]. - UnitedHealthcare currently trades at 16 times forward earnings, which is a premium compared to peers, indicating potential for further multiple compression as the company's growth narrative is under pressure [15].

Last year was a forgettable one for DaVita (NYSE: DVA) shareholders, but understandably so. The stock ended up losing 25% of its value in calendar 2025 due to a combination of a declining number of dialysis patients, subpar guidance for most of the year, uncertainty as to how much insurers were willing to continue reimbursing the company, and an embarrassing ransomware attack reported in April. It's just possible, however, that the sellers overshot their target. As of 12:16 p.m. ET Tuesday, DaVita stock ...

Core Viewpoint - DaVita Inc. reported strong fourth-quarter earnings and provided optimistic guidance for fiscal 2026, leading to a significant increase in stock price [1]. Earnings Summary - Adjusted earnings were $3.40 per share, surpassing the consensus estimate of $3.16 [2]. - Sales reached $3.62 billion, reflecting a year-over-year increase of 5.8% and exceeding the consensus of $3.497 billion [2]. - Revenue per treatment increased from $410.59 to $422.60, driven by higher average reimbursement rates and seasonal factors [2]. Year-to-Date Changes - The year-to-date performance was influenced by the inclusion of phosphate binders in the ESRD Prospective Payment System and annual increases in average reimbursement rates, including Medicare [3]. - Total U.S. dialysis treatments for Q4 2025 were 7,264,520, averaging 91,608 treatments per day, which is a slight decrease of 0.1% from Q3 2025 [3]. Cost and Treatment Growth - Normalized non-acquired treatment growth for Q4 2025 compared to Q4 2024 was down by 0.6% [4]. - Patient care costs per treatment rose from $273.54 to $279.60, primarily due to increased health benefit expenses and medical supply costs [4]. Guidance - For fiscal 2026, DaVita anticipates adjusted earnings between $13.60 and $15.00 per share, exceeding the consensus of $12.65 [5]. - Adjusted operating income is expected to range from $2.09 billion to $2.24 billion, with treatment volume projected to remain flat compared to 2025 [5]. - Revenue per treatment is expected to grow by approximately 1% to 2%, while cost growth is anticipated to be between 1.25% and 2.25% [5]. Additional Investments - DaVita's CFO mentioned an estimated $40 million headwind from the expiration of enhanced premium tax credits, which is offset by the removal of a $45 million headwind from a previous cyber incident [6]. - DaVita is making a minority investment of approximately $200 million in Elara Caring, which is expected to positively impact other income lines [7]. Analyst View - Barclays has maintained an Equal-Weight rating on DaVita and raised the price target from $143 to $158 [8]. - Following the earnings report, DaVita's stock rose by 21.69% to $135.31 [8].

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.The Dow traded down 0.19% to 49,316.23 while the NASDAQ dipped 1.23% to 23,302.18. The S&P 500 also fell, dropping, 0.62% to 6,933.29.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsMaterials shares gained by 1.8% on Tuesday.In trading on Tuesday, information technology stocks fell by 1.9%.Top HeadlineOn Tuesday, Pfizer Inc. (NYSE:PFE) sh ...

Key Takeaways DVA posted Q4 adjusted EPS of $3.40 and revenue of $3.62 billion, both beating the Zacks Consensus Estimate.DaVita expanded gross margin by 98 bps to 33.4% and lifted adjusted operating margin to 20.4% in Q4.DVA issued 2026 adjusted EPS guidance of $13.60 to $15.00 and expects RPT growth of 1% to 2%.DaVita Inc. (DVA) delivered adjusted earnings per share (EPS) from continuing operations of $3.40 in the fourth quarter of 2025, up 51.8% year over year. The figure surpassed the Zacks Consensus Es ...

DaVita posts adjusted beats earnings expectations and posts 9.9% revenue growth in the third quarter. ...